
AbstractThroughout the last decades, vaccination has been key to prevent and eradicate infectious diseases. However, many pathogens (e.g. respiratory syncytial virus (RSV), influenza, dengue and others) have resisted vaccine development efforts, largely due to the failure to induce potent antibody responses targeting conserved epitopes. Deep profiling of human B-cells often reveals potent neutralizing antibodies that emerge from natural infection, but these specificities are generally subdominant (i.e., are present in low titers). A major challenge for next-generation vaccines is to overcome established immunodominance hierarchies and focus antibody responses on crucial neutralization epitopes. Here, we show that a computationally designed epitope-focused immunogen presenting a single RSV neutralization epitope elicits superior epitope-specific responses compared to the viral fusion protein. In addition, the epitope-focused immunogen efficiently boosts antibodies targeting the Palivizumab epitope, resulting in enhanced neutralization. Overall, we show that epitope-focused immunogens can boost subdominant neutralizing antibody responsesin vivoand reshape established antibody hierarchies.
570, rsv antibody, [SDV.IMM] Life Sciences [q-bio]/Immunology, QH301-705.5, [SDV]Life Sciences [q-bio], respiratory syncytial virus, Recombinant Fusion Proteins, Genetic Vectors, 610, Gene Expression, Receptors, Antigen, B-Cell, hiv, dependent enhancement, Antibodies, Monoclonal, Humanized, Antibodies, Viral, Epitopes, Mice, Immunogenicity, Vaccine, 616, Escherichia coli, Respiratory Syncytial Virus Vaccines, Animals, Biology (General), Cloning, Molecular, Palivizumab, hemagglutinin-stem, Mice, Inbred BALB C, dengue virus, respiratory syncytial virus;fusion-glycoprotein vaccine;structural basis;dependent enhancement;hemagglutinin-stem;dengue virus;rsv antibody;hiv;infection;cells, structural basis, fusion-glycoprotein vaccine, Antibodies, Neutralizing, infection, [SDV] Life Sciences [q-bio], [SDV.IMM]Life Sciences [q-bio]/Immunology, cells, Computer-Aided Design, Nanoparticles, Female, Immunization, Research Article
570, rsv antibody, [SDV.IMM] Life Sciences [q-bio]/Immunology, QH301-705.5, [SDV]Life Sciences [q-bio], respiratory syncytial virus, Recombinant Fusion Proteins, Genetic Vectors, 610, Gene Expression, Receptors, Antigen, B-Cell, hiv, dependent enhancement, Antibodies, Monoclonal, Humanized, Antibodies, Viral, Epitopes, Mice, Immunogenicity, Vaccine, 616, Escherichia coli, Respiratory Syncytial Virus Vaccines, Animals, Biology (General), Cloning, Molecular, Palivizumab, hemagglutinin-stem, Mice, Inbred BALB C, dengue virus, respiratory syncytial virus;fusion-glycoprotein vaccine;structural basis;dependent enhancement;hemagglutinin-stem;dengue virus;rsv antibody;hiv;infection;cells, structural basis, fusion-glycoprotein vaccine, Antibodies, Neutralizing, infection, [SDV] Life Sciences [q-bio], [SDV.IMM]Life Sciences [q-bio]/Immunology, cells, Computer-Aided Design, Nanoparticles, Female, Immunization, Research Article
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 34 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
